Mesa Laboratories (NASDAQ:MLAB) CAO Sells $11,949.86 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CAO Lyndsey Elizabeth Crennen sold 118 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $101.27, for a total value of $11,949.86. Following the transaction, the chief accounting officer directly owned 1,473 shares in the company, valued at approximately $149,170.71. This represents a 7.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mesa Laboratories Price Performance

Shares of MLAB stock opened at $95.10 on Friday. Mesa Laboratories, Inc. has a 52-week low of $55.45 and a 52-week high of $113.99. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.72. The firm has a market capitalization of $525.43 million, a P/E ratio of 79.25 and a beta of 0.94. The stock has a 50 day moving average price of $101.94 and a 200 day moving average price of $90.77.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The business had revenue of $63.72 million for the quarter, compared to analysts’ expectations of $65.21 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. During the same quarter in the previous year, the firm earned ($1.31) EPS.

Mesa Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Friday, May 29th were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, May 29th. Mesa Laboratories’s payout ratio is currently 53.33%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average price target of $94.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its position in shares of Mesa Laboratories by 5.9% in the 1st quarter. Bank of America Corp DE now owns 57,871 shares of the medical instruments supplier’s stock worth $5,117,000 after purchasing an additional 3,207 shares during the period. Royal Bank of Canada increased its holdings in Mesa Laboratories by 143.3% during the first quarter. Royal Bank of Canada now owns 13,275 shares of the medical instruments supplier’s stock valued at $1,173,000 after buying an additional 7,818 shares during the period. Quantinno Capital Management LP increased its holdings in Mesa Laboratories by 17.9% during the first quarter. Quantinno Capital Management LP now owns 4,318 shares of the medical instruments supplier’s stock valued at $382,000 after buying an additional 657 shares during the period. Lazard Asset Management LLC bought a new position in Mesa Laboratories in the first quarter worth approximately $1,797,000. Finally, Renaissance Technologies LLC lifted its holdings in Mesa Laboratories by 802.9% during the first quarter. Renaissance Technologies LLC now owns 31,600 shares of the medical instruments supplier’s stock worth $2,794,000 after buying an additional 28,100 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.